Personalis

Personalis Current Liabilities

The Current Liabilities of Personalis (PSNL) as of Oct 11, 2026 is 38.07 M USD. In the previous year, Current Liabilities was 45.93 M USD — a change of -17.13% (lower).

Current Liabilities

38.07 MUSD

YoY

-17.13%

Last updated:

Current Liabilities of Personalis is 2025 38.07 M USD. Current Liabilities of Personalis was 2024 45.93 M USD. It decreases by -17.13% lower compared to the previous year.

The Personalis Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
18.05 M USD
Jan 1, 2019
19.97 M USD
Jan 1, 2020
30.31 M USD
Jan 1, 2021
43.93 M USD
Jan 1, 2022
50.01 M USD
Jan 1, 2023
66.99 M USD
Jan 1, 2024
45.93 M USD
Jan 1, 2025
38.07 M USD
The Personalis Current Liabilities history
YEARCurrent LiabilitiesYoY
38.07 MUSD-17.13%
45.93 MUSD-31.43%
66.99 MUSD+33.94%
50.01 MUSD+13.85%
43.93 MUSD+44.94%
30.31 MUSD+51.72%
19.97 MUSD+10.66%
18.05 MUSD-32.85%
26.88 MUSD—
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

Current Liabilities of Personalis is 38.07 M USD in 2025.

Current Liabilities of Personalis changed from 45.93 M USD to 38.07 M USD, representing a -17.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Personalis since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Personalis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Personalis

All Key Metrics — Personalis